Logo image of TRVI

TREVI THERAPEUTICS INC (TRVI) Stock Price, Quote, News and Overview

NASDAQ:TRVI - Nasdaq - US89532M1018 - Common Stock - Currency: USD

7.33  -0.08 (-1.01%)

After market: 7.33 0 (0%)

TRVI Quote, Performance and Key Statistics

TREVI THERAPEUTICS INC

NASDAQ:TRVI (8/1/2025, 8:07:19 PM)

After market: 7.33 0 (0%)

7.33

-0.08 (-1.01%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High8.11
52 Week Low2.36
Market Cap859.74M
Shares117.29M
Float104.94M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07 2025-08-07
IPO05-07 2019-05-07


TRVI short term performance overview.The bars show the price performance of TRVI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80

TRVI long term performance overview.The bars show the price performance of TRVI in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of TRVI is 7.33 USD. In the past month the price increased by 23.19%. In the past year, price increased by 154.96%.

TREVI THERAPEUTICS INC / TRVI Daily stock chart

TRVI Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 55.4 722.49B
JNJ JOHNSON & JOHNSON 16.73 402.99B
AZN ASTRAZENECA PLC-SPONS ADR 16.66 229.28B
NVS NOVARTIS AG-SPONSORED ADR 13.03 223.20B
NVO NOVO-NORDISK A/S-SPONS ADR 13.42 214.13B
MRK MERCK & CO. INC. 10.3 199.10B
PFE PFIZER INC 7.32 133.55B
SNY SANOFI-ADR 12.08 114.02B
BMY BRISTOL-MYERS SQUIBB CO 6.57 90.01B
GSK GSK PLC-SPON ADR 8.48 75.79B
ZTS ZOETIS INC 24.48 65.62B
TAK TAKEDA PHARMACEUTIC-SP ADR 48.83 44.72B

About TRVI

Company Profile

TRVI logo image Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. The company is headquartered in New Haven, Connecticut and currently employs 26 full-time employees. The company went IPO on 2019-05-07. The firm is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. The company has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Company Info

TREVI THERAPEUTICS INC

195 Church St Fl 14

New Haven CONNECTICUT 06510 US

CEO: Jennifer Good

Employees: 26

TRVI Company Website

TRVI Investor Relations

Phone: 12033042499

TREVI THERAPEUTICS INC / TRVI FAQ

What is the stock price of TREVI THERAPEUTICS INC today?

The current stock price of TRVI is 7.33 USD. The price decreased by -1.01% in the last trading session.


What is the ticker symbol for TREVI THERAPEUTICS INC stock?

The exchange symbol of TREVI THERAPEUTICS INC is TRVI and it is listed on the Nasdaq exchange.


On which exchange is TRVI stock listed?

TRVI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for TREVI THERAPEUTICS INC stock?

15 analysts have analysed TRVI and the average price target is 22.03 USD. This implies a price increase of 200.57% is expected in the next year compared to the current price of 7.33. Check the TREVI THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is TREVI THERAPEUTICS INC worth?

TREVI THERAPEUTICS INC (TRVI) has a market capitalization of 859.74M USD. This makes TRVI a Small Cap stock.


How many employees does TREVI THERAPEUTICS INC have?

TREVI THERAPEUTICS INC (TRVI) currently has 26 employees.


What are the support and resistance levels for TREVI THERAPEUTICS INC (TRVI) stock?

TREVI THERAPEUTICS INC (TRVI) has a support level at 7.32. Check the full technical report for a detailed analysis of TRVI support and resistance levels.


Should I buy TREVI THERAPEUTICS INC (TRVI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does TREVI THERAPEUTICS INC (TRVI) stock pay dividends?

TRVI does not pay a dividend.


When does TREVI THERAPEUTICS INC (TRVI) report earnings?

TREVI THERAPEUTICS INC (TRVI) will report earnings on 2025-08-07.


What is the Price/Earnings (PE) ratio of TREVI THERAPEUTICS INC (TRVI)?

TREVI THERAPEUTICS INC (TRVI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.45).


What is the Short Interest ratio of TREVI THERAPEUTICS INC (TRVI) stock?

The outstanding short interest for TREVI THERAPEUTICS INC (TRVI) is 9.48% of its float. Check the ownership tab for more information on the TRVI short interest.


TRVI Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to TRVI. When comparing the yearly performance of all stocks, TRVI is one of the better performing stocks in the market, outperforming 95.87% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TRVI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TRVI. TRVI has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TRVI Financial Highlights

Over the last trailing twelve months TRVI reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by -32.35% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -43.92%
ROE -47.25%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%18.18%
Sales Q2Q%N/A
EPS 1Y (TTM)-32.35%
Revenue 1Y (TTM)N/A

TRVI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to TRVI. The Buy consensus is the average rating of analysts ratings from 15 analysts.


Ownership
Inst Owners66.07%
Ins Owners13.68%
Short Float %9.48%
Short Ratio4.89
Analysts
Analysts86.67
Price Target22.03 (200.55%)
EPS Next Y8.42%
Revenue Next YearN/A